×
Repligen Inventory 2010-2024 | RGEN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Repligen inventory for the quarter ending June 30, 2024 was
$0.191B
, a
20.9% decline
year-over-year.
Repligen inventory for 2023 was
$0.202B
, a
15.09% decline
from 2022.
Repligen inventory for 2022 was
$0.238B
, a
29.15% increase
from 2021.
Repligen inventory for 2021 was
$0.184B
, a
94.15% increase
from 2020.
View More
Repligen Inventory 2010-2024 | RGEN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Repligen inventory for 2023 was
$0.202B
, a
15.09% decline
from 2022.
Repligen inventory for 2022 was
$0.238B
, a
29.15% increase
from 2021.
Repligen inventory for 2021 was
$0.184B
, a
94.15% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.9B
Regeneron Pharmaceuticals (REGN)
$125.5B
Vertex Pharmaceuticals (VRTX)
$122.4B
Gilead Sciences (GILD)
$104.4B
Bristol Myers Squibb (BMY)
$100.8B
CSL (CSLLY)
$96.8B
GSK (GSK)
$87.9B
Alnylam Pharmaceuticals (ALNY)
$35.1B
Argenex SE (ARGX)
$31.6B
Biogen (BIIB)
$28.8B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$26.9B
Illumina (ILMN)
$20.9B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.3B
BioMarin Pharmaceutical (BMRN)
$13.5B
Vaxcyte (PCVX)
$13B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.5B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.4B
Bio-Rad Laboratories (BIO.B)
$9.1B
Legend Biotech (LEGN)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.7B
Halozyme Therapeutics (HALO)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.9B
Exelixis (EXEL)
$7.7B